It also showed that the public cost of expanding public coverage
for high - cost drugs — such as
treatments for cancer and rheumatoid arthritis — would be modest and,
under most plausible scenarios, would be offset by savings achieved in relatively common drug classes — like
treatments for high cholesterol and
high blood pressure.